Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice

Virology

Volumn 406, Issue 1, 2010, Pages 80-87

  Lau, Yuk Fai ^a,b   Tang, Lay Hoon ^b   Ooi, Eng Eong ^b   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DSO NATIONAL LABORATORIES   (Singapore)

Author keywords

Immunoprophylaxis; Influenza; TLR3

Indexed keywords

OSELTAMIVIR; PIKA; RNA DERIVATIVE; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CYTOKINE; DOUBLE STRANDED RNA; TLR3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA A (H6N1); INFLUENZA A (H7N1); INFLUENZA A (H9N2); INFLUENZA VIRUS A; INFLUENZA VIRUS A H6N1; INFLUENZA VIRUS A H7N1; INFLUENZA VIRUS A H9N2; INNATE IMMUNITY; LUNG INFILTRATE; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROTECTION; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DEFICIENCY; DRUG EFFECTS; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLUENZA VIRUS A H5N1; KNOCKOUT MOUSE; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CYTOKINES; FEMALE; HOST-PATHOGEN INTERACTIONS; IMMUNITY, INNATE; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; LUNG; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; RNA, DOUBLE-STRANDED; TOLL-LIKE RECEPTOR 3; VIRUS REPLICATION;

INFLUENZA A VIRUS; MUS; SUIDAE;

EID: 77956181076     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.07.008     Document Type: Article

References (62)

1. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413(6857):732-738.
2. Arimura H. Correlation between molecular size and interferon-inducing activity of poly I:C. Acta Virol. 1975, 19(6):457-466.
3. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., Lochindarat S., Nguyen T.K., Nguyen T.H., Tran T.H., Nicoll A., Touch S., Yuen K.Y. Avian influenza A (H5N1) infection in humans. N Engl J. Med. 2005, 353(13):1374-1385.
4. Bernstein D.I., Harrison C.J., Tomai M.A., Miller R.L. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J. Infect. Dis. 2001, 183(6):844-849.
5. Butt K.M., Smith G.J., Chen H., Zhang L.J., Leung Y.H., Xu K.M., Lim W., Webster R.G., Yuen K.Y., Peiris J.S., Guan Y. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J. Clin. Microbiol. 2005, 43(11):5760-5767.
6. Centers for Disease Control and Prevention Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)-United States, May-August 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58(38):1071-1074.
7. Centers for Disease Control and Prevention Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58(15):400-402.
8. Chen M., Griffith B.P., Lucia H.L., Hsiung G.D. Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob. Agents Chemother. 1988, 32(5):678-683.
9. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J. Med. 2005, 353(25):2667-2672.
10. De Miranda J., Yaddanapudi K., Hornig M., Lipkin W.I. Astrocytes recognize intracellular polyinosinic-polycytidylic acid via MDA-5. FASEB J. 2009, 23(4):1064-1071.
11. Deliyannis G., Jackson D.C., Dyer W., Bates J., Coulter A., Harling-McNabb L., Brown L.E. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine 1998, 16(20):2058-2068.
12. Dorner B.G., Scheffold A., Rolph M.S., Huser M.B., Kaufmann S.H., Radbruch A., Flesch I.E., Kroczek R.A. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc. Natl Acad. Sci. USA 2002, 99(9):6181-6186.
13. Fujisawa H. Neutrophils play an essential role in cooperation with antibody in both protection against and recovery from pulmonary infection with influenza virus in mice. J. Virol. 2008, 82(6):2772-2783.
14. Fujisawa H., Tsuru S., Taniguchi M., Zinnaka Y., Nomoto K. Protective mechanisms against pulmonary infection with influenza virus. I. Relative contribution of polymorphonuclear leukocytes and of alveolar macrophages to protection during the early phase of intranasal infection. J. Gen. Virol. 1987, 68(Pt 2):425-432.
15. Gillim-Ross L., Santos C., Chen Z., Aspelund A., Yang C.F., Ye D., Jin H., Kemble G., Subbarao K. Avian influenza H6 viruses productively infect and cause illness in mice and ferrets. J. Virol. 2008, 82(21):10854-10863.
16. Gitlin L., Barchet W., Gilfillan S., Cella M., Beutler B., Flavell R.A., Diamond M.S., Colonna M. Essential role of MDA-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 2006, 103(22):8459-8464.
17. Harrison C.J., Miller R.L., Bernstein D.I. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. 1994, 38(9):2059-2064.
18. Hashimoto Y., Moki T., Takizawa T., Shiratsuchi A., Nakanishi Y. Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J. Immunol. 2007, 178(4):2448-2457.
19. Hayden F.G. Antiviral resistance in influenza viruses-implications for management and pandemic response. N Engl J. Med. 2006, 354(8):785-788.
20. Hayden F.G. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res. 2006, 71(2-3):372-378.
21. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., Kinnersley N., Mills R.G., Ward P., Straus S.E. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999, 282(13):1240-1246.
22. Herold S., Steinmueller M., von Wulffen W., Cakarova L., Pinto R., Pleschka S., Mack M., Kuziel W.A., Corazza N., Brunner T., Seeger W., Lohmeyer J. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J. Exp. Med. 2008, 205(13):3065-3077.
23. Hurt A.C., Selleck P., Komadina N., Shaw R., Brown L., Barr I.G. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007, 73(3):228-231.
24. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., Black S., Shinefield H., Fukuda K. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J. Med. 2000, 342(4):232-239.
25. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19(2):225-234.
26. Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., Hiiragi A., Dermody T.S., Fujita T., Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 2008, 205(7):1601-1610.
27. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364(9436):759-765.
28. Kugel D., Kochs G., Obojes K., Roth J., Kobinger G.P., Kobasa D., Haller O., Staeheli P., von Messling V. Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J. Virol. 2009, 83(8):3843-3851.
29. Kumar H., Koyama S., Ishii K.J., Kawai T., Akira S. Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J. Immunol. 2008, 180(2):683-687.
30. Lau Y.F., Deliyannis G., Zeng W., Mansell A., Jackson D.C., Brown L.E. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int. Immunol. 2006, 18(12):1801-1813.
31. Lau Y.F., Tang L.H., Ooi E.E. A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 2009, 27(9):1354-1364.
32. Le Goffic R., Balloy V., Lagranderie M., Alexopoulou L., Escriou N., Flavell R., Chignard M., Si-Tahar M. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. 2006, 2(6):e53.
33. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437(7062):1108.
34. Lipatov A.S., Govorkova E.A., Webby R.J., Ozaki H., Peiris M., Guan Y., Poon L., Webster R.G. Influenza: emergence and control. J. Virol. 2004, 78(17):8951-8959.
35. McKimm-Breschkin J.L., Selleck P.W., Usman T.B., Johnson M.A. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 2007, 13(9):1354-1357.
36. Morens D.M., Taubenberger J.K., Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 2008, 198(7):962-970.
37. Morrey J.D., Day C.W., Julander J.G., Blatt L.M., Smee D.F., Sidwell R.W. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir. Chem. Chemother. 2004, 15(2):101-109.
38. Nakano H., Yanagita M., Gunn M.D. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 2001, 194(8):1171-1178.
39. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J. Med. 2000, 342(4):225-231.
40. Nicholson K.G., Wood J.M., Zambon M. Influenza. Lancet 2003, 362(9397):1733-1745.
41. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., Orr W.K., Shortridge K.F. Human infection with influenza H9N2. Lancet 1999, 354(9182):916-917.
42. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14(4):778-809. table of contents.
43. Saravolac E.G., Sabuda D., Crist C., Blasetti K., Schnell G., Yang H., Kende M., Levy H.B., Wong J.P. Immunoprophylactic strategies against respiratory influenza virus infection. Vaccine 2001, 19(17-19):2227-2232.
44. Seo S.H., Webster R.G. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J. Virol. 2002, 76(3):1071-1076.
45. Stokes J.R., Sorkness R.L., Kaplan M.R., Castleman W.L., Tomai M.A., Miller R.L., Lemanske R.F. Attenuation of virus-induced airway dysfunction in rats treated with imiquimod. Eur. Respir. J. 1998, 11(2):324-329.
46. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., Hemphill M., Rowe T., Shaw M., Xu X., Fukuda K., Cox N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279(5349):393-396.
47. Sun K., Metzger D.W. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat. Med. 2008, 14(5):558-564.
48. Tate M.D., Brooks A.G., Reading P.C. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir. Res. 2008, 9:57.
49. Thitithanyanont A., Engering A., Ekchariyawat P., Wiboon-ut S., Limsalakpetch A., Yongvanitchit K., Kum-Arb U., Kanchongkittiphon W., Utaisincharoen P., Sirisinha S., Puthavathana P., Fukuda M.M., Pichyangkul S. High susceptibility of human dendritic cells to avian influenza H5N1 virus infection and protection by IFN-alpha and TLR ligands. J. Immunol. 2007, 179(8):5220-5227.
50. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., Singh S., Kinnersley N., Ward P., Mills R.G. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000, 283(8):1016-1024.
51. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 2007, 7(3):179-190.
52. + T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl Acad. Sci. USA 2008, 105(7):2574-2579.
53. Tumpey T.M., Garcia-Sastre A., Taubenberger J.K., Palese P., Swayne D.E., Pantin-Jackwood M.J., Schultz-Cherry S., Solorzano A., Van Rooijen N., Katz J.M., Basler C.F. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J. Virol. 2005, 79(23):14933-14944.
54. Tumpey T.M., Szretter K.J., Van Hoeven N., Katz J.M., Kochs G., Haller O., Garcia-Sastre A., Staeheli P. The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J. Virol. 2007, 81(19):10818-10821.
55. Tuvim M.J., Evans S.E., Clement C.G., Dickey B.F., Gilbert B.E. Augmented lung inflammation protects against influenza A pneumonia. PLoS ONE 2009, 4(1):e4176.
56. Van Hoeven N., Belser J.A., Szretter K.J., Zeng H., Staeheli P., Swayne D.E., Katz J.M., Tumpey T.M. Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J. Virol. 2009, 83(7):2851-2861.
57. Wong J.P., Saravolac E.G., Sabuda D., Levy H.B., Kende M. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob. Agents Chemother. 1995, 39(11):2574-2576.
58. Wong J.P., Yang H., Nagata L., Kende M., Levy H., Schnell G., Blasetti K. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine 1999, 17(13-14):1788-1795.
59. Wong J.P., Nagata L.P., Christopher M.E., Salazar A.M., Dale R.M. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine 2005, 23(17-18):2266-2268.
60. Wong J.P., Christopher M.E., Salazar A.M., Dale R.M., Sun L.Q., Wang M. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine 2007, 25(16):3175-3178.
61. Wong J.P., Christopher M.E., Viswanathan S., Karpoff N., Dai X., Das D., Sun L.Q., Wang M., Salazar A.M. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 2009, 27(25-26):3481-3483.
62. Yen H.L., Monto A.S., Webster R.G., Govorkova E.A. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 2005, 192(4):665-672.